Why the study?
Does a polypill containing aspirin, ramipril, and atorvastatin reduce major adverse cardiovascular events in patients within 6 months after myocardial infarction?
Does a polypill containing aspirin, ramipril, and atorvastatin reduce major adverse cardiovascular events in patients within 6 months after myocardial infarction?
A polypill strategy containing aspirin, ramipril, and atorvastatin significantly reduces the risk of major adverse cardiovascular events compared to usual care in secondary prevention post-myocardial infarction.
Answers are grounded in this paper and cite their sources.
Supports polypill use for post-MI secondary prevention; extends evidence for fixed-dose combinations in high-risk patients.
Treatment with a polypill containing aspirin, ramipril, and atorvastatin within 6 months after myocardial infarction resulted in a significantly lower risk of major adverse cardiovascular events than usual care. (Funded by the European Union Horizon 2020; SECURE ClinicalTrials.gov number, NCT02596126; EudraCT number, 2015-002868-17.).
No takes yet. Share an insight, caveat, or question.
Castellano et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: